Vpriv (velaglucerase alfa) (Velaglucerase Alfa INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 2.5 mg/mL

Vpriv (velaglucerase alfa) is an intravenous enzyme replacement therapy approved by the FDA for the treatment of Gaucher Type I Disease, a rare lysosomal storage disorder. It received orphan drug designation and is manufactured by Takeda Pharmaceuticals U.S.A., Inc. This therapeutic agent falls within the neurology and genetics therapeutic areas.

Strength

2.5 mg/mL

Pack Size

1 VIAL, GLASS in 1 BOX (54092-701-04) / 4 mL in 1 VIAL, GLASS

Manufacturer / TM Owner

Takeda Pharmaceuticals U.S.A., Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vpriv is indicated for the treatment of Gaucher Type I Disease, a rare genetic disorder caused by deficiency of the enzyme glucocerebrosidase, leading to accumulation of glucocerebroside in macrophages throughout the body. The drug is administered intravenously to patients with confirmed Gaucher Type I Disease who experience hepatosplenomegaly, bone disease, or hematologic manifestations. Vpriv works by providing exogenous glucocerebrosidase enzyme replacement, facilitating the breakdown of accumulated glucocerebroside and reducing pathological substrate accumulation. The patient population includes both pediatric and adult patients diagnosed with Type I Gaucher Disease. By restoring enzymatic activity, Vpriv helps alleviate organ involvement, improve hematologic parameters, and reduce disease-related complications, thereby improving quality of life and disease outcomes in this severely affected population.

Side Effects

Common adverse events associated with Vpriv include infusion-related reactions such as fever, chills, flushing, and hypotension, which may occur during or shortly after administration. Serious adverse events include anaphylaxis, severe infusion reactions, and potential immunogenicity with development of anti-drug antibodies. Patients may experience headache, fatigue, nausea, and arthralgia. Monitoring requirements include vital signs during infusions, periodic assessment of disease biomarkers (chitotriosidase, angiotensin-converting enzyme), organ function tests, and surveillance for infusion reactions. Regular hematologic and hepatic monitoring is essential to assess therapeutic response and detect potential complications.

Precautions & Warnings

Vpriv is contraindicated in patients with known hypersensitivity to velaglucerase alfa or any excipients. Severe infusion reactions and anaphylaxis have been reported; appropriate medical support must be available during administration. Use with caution in patients with compromised cardiopulmonary function. Pregnancy Category C; limited data exist regarding use in pregnant women, requiring careful risk-benefit assessment. Pediatric use is supported by clinical evidence, though dosing adjustments may be necessary. No specific dose adjustments are required for renal or hepatic impairment, though caution is advised in severe hepatic disease. Patients should be monitored for development of IgG antibodies that may reduce drug efficacy.

Avoid Interactions

Limited drug-drug interactions have been formally documented with Vpriv. No significant interactions with common medications are anticipated, as velaglucerase alfa is a recombinant enzyme unlikely to undergo hepatic metabolism or affect cytochrome P450 enzymes. However, concurrent use of other enzyme replacement therapies or substrate reduction inhibitors for Gaucher Disease should be coordinated with healthcare providers. Patients should inform their physician of all concurrent medications and supplements prior to treatment initiation.

Frequently Asked Questions

Vpriv is used to treat Gaucher Type I Disease, a rare genetic disorder characterized by deficiency of the glucocerebrosidase enzyme. It is administered intravenously to reduce the accumulation of glucocerebroside in the body and alleviate symptoms including hepatosplenomegaly, bone disease, and hematologic abnormalities.

Vpriv is administered as an intravenous infusion. The typical dosing regimen is 60 units/kg administered intravenously every other week, though dosing may be individualized based on patient response and clinical parameters. Each infusion is diluted in normal saline and administered over approximately 60 minutes.

Common side effects include infusion-related reactions such as fever, chills, flushing, and hypotension. Patients may also experience headache, fatigue, nausea, and joint pain. Serious reactions including anaphylaxis, though rare, can occur and require immediate medical attention.

Vpriv is manufactured by Takeda Pharmaceuticals U.S.A., Inc., a leading global pharmaceutical company specializing in rare genetic and metabolic disorders.

Yes, Vpriv received FDA orphan drug designation for the treatment of Gaucher Type I Disease. This designation recognizes its importance in treating a rare disease affecting a limited patient population and provides regulatory incentives to support its development and commercialization.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.